Topline data from the TRIUMPH-2 and TRIUMPH-3 trials show substantial weight loss, improved glycemic control, and favorable changes in cardiometabolic risk markers with the investigational triple hormone receptor agonist in adults with obesity and type 2 diabetes or established cardiovascular disease.

A new Endocrine Society statement has reinforced the importance of accurate diagnosis and appropriate clinical assessment before testosterone replacement therapy (TRT) is initiated in men with hypogonadism.1 Published July 16, 2026, the statement reiterates that treatment should not be based on symptoms alone and highlights continuing uncertainties around the long-term safety of TRT. It follows an FDA expert panel that reviewed testosterone eligibility criteria in December 2025, Society comments submitted to the FDA in February 2026, and new prescribing-pattern data presented at ENDO 2026, the Society's annual meeting, in June.

In a cross-sectional study of 6,996 patients with type 2 diabetes published in Endocrine, elevated serum uric acid was associated with higher odds of prevalent diabetic retinopathy (DR) among those diagnosed before 65 years of age, but not among those diagnosed at 65 years or older.1

Achieving clinically meaningful weight loss and cardiometabolic targets is a key goal in the management of obesity and type 2 diabetes, particularly in people at elevated cardiovascular risk. In this analysis of the phase 3 STEP UP T2D trial, researchers evaluated the extent to which participants treated with semaglutide 7.2 mg, semaglutide 2.4 mg or placebo achieved predefined BMI, waist-to-height ratio and cardiometabolic targets after 72 weeks. In this interview, Prof. Carel le Roux discusses the rationale for assessing these treatment targets, the key findings from the analysis and their implications for the use of higher-dose semaglutide in people with obesity and type 2 diabetes.

At ECE 2026, Evelien Gevers discussed data showing DCCR reduced hyperphagia in Prader–Willi syndrome and remained generally safe in patients with pre-diabetes or diabetes, supporting broader clinical confidence and access.

New data presented at ENDO 2026 highlighted the continued evolution of endocrine care, with studies spanning rare disease management, long-term hormone replacement, artificial intelligence-supported screening and real-world treatment outcomes. Across several presentations, investigators reported sustained improvements in biochemical, metabolic, skeletal and patient-reported outcomes, while also emphasising the importance of long-term follow-up and careful interpretation of emerging data.

Data presented at ENDO 2026 highlighted investigational approaches for difficult-to-control type 2 diabetes and acquired hypothalamic obesity, real-world outcomes with tirzepatide, and wider health impacts of GLP-1-based therapy.

A new Endocrine Society Clinical Practice Guideline recommends a more selective approach to diagnostic testing and treatment for children with suspected central precocious puberty (CPP), particularly in children whose early pubertal signs are mild or slowly progressive.1,2

Adults with prediabetes who received an intensive lifestyle intervention in the Diabetes Prevention Program were less likely to develop multiple chronic conditions over long-term follow-up than those assigned to placebo, according to an analysis published in JAMA.1 A similar reduction was not observed with metformin.